|
|
1. Dr Goodman played a leadership role in developing FDA's Regulatory Science Strategic Plan and Medical Countermeasures Initiative and has worked extensively and collaboratively, interacting with industry, academia, government and global public health and regulatory partners to prepare for and respond to major public health threats, including emerging infectious diseases, disasters and terrorism. He led FDA's response to West Nile Virus and to the 2009 H1N1 influenza pandemic and served on the Senior Leadership Team for the 2010 White House Medical Countermeasure Review. He played a key role in facilitating development of and access to a variety of medical countermeasures, including pandemic influenza vaccines, during his FDA tenure, and served as a member of the Decade of Vaccines Research and Development Working Group, which contributed to the 2012 Global Vaccine Action Plan. He also was appointed by the White House to the US Federal Coordinating Council on Comparative Effectiveness Research. As Senior Advisor to the FDA Commissioner from 1998-9, Dr Goodman co-chaired the US Task Force on Antimicrobial Resistance, producing the first Public Health Action Plan to Combat Antimicrobial Resistance. Prior to joining the FDA, he was Director of the Division of Infectious Diseases and Professor of Medicine at the University of Minnesota, where he led several clinical studies of new anti-infectives and where his research laboratory isolated Anaplasma phagocytophilum, the causative agent of a new tick borne disease, human granulocytic anaplasmosis.
|
|
|
2. As Non-Executive Director of GSK, Dr Goodman will receive standard annual fees of £85,000 per annum. He will also receive a further £30,000 in respect of his additional duties as a Board Scientific and Medical Expert. To enhance the link between Non-Executive Directors and shareholders, at least 25% of his fees will be deducted and at a later date converted into GSK ADSs.
|
|
|
|
|
|
3. The Board has determined that Dr Goodman will be an independent Non-Executive Director, in accordance with the UK Corporate Governance Code. In addition, the Company confirms that there are no further disclosures to be made in connection with Dr Goodman's appointment in accordance with Listing Rule 9.6.13R.
|
|
|
4. With effect from 1 January 2016, the composition of the Board of GSK will be as follows:
|
|
Sir Philip Hampton
|
Non-Executive Chairman
|
|
Sir Andrew Witty
|
Chief Executive Officer
|
|
Mr Simon Dingemans
|
Chief Financial Officer
|
|
Dr Moncef Slaoui
|
Chairman, Global Vaccines
|
|
Professor Sir Roy Anderson
|
Independent Non-Executive Director
|
|
Mr Vindi Banga
|
Senior Independent Non-Executive Director Designate
|
|
Dr Stephanie Burns
|
Independent Non-Executive Director
|
|
Ms Stacey Cartwright
|
Independent Non-Executive Director
|
|
Ms Lynn Elsenhans
Dr Jesse Goodman
|
Independent Non-Executive Director
Independent Non-Executive Director
|
|
Ms Judy Lewent
|
Independent Non-Executive Director
|
|
Sir Deryck Maughan
|
Senior Independent Non-Executive Director
|
|
Dr Daniel Podolsky
|
Independent Non-Executive Director
|
|
Mr Hans Wijers
|
Independent Non-Executive Director
|
|
Mr Urs Rohner
|
Independent Non-Executive Director
|
|
GSK enquiries:
|
|||
|
UK Media enquiries:
|
David Mawdsley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
US Media enquiries:
|
Sarah Alspach
|
+1 202 715 1048
|
(Washington, DC)
|
|
Sarah Spencer
|
+1 215 751 3335
|
(Philadelphia)
|
|
|
Jenni Ligday
|
+1 202 715 1049
|
(Washington, DC)
|
|
|
Analyst/Investor enquiries:
|
Ziba Shamsi
|
+44 (0) 20 8047 5543
|
(London)
|
|
Tom Curry
|
+ 1 215 751 5419
|
(Philadelphia)
|
|
|
Gary Davies
|
+44 (0) 20 8047 5503
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014.
|
|
Registered in England & Wales:
No. 3888792
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|